A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer

E. H. Tan, R. Ramlau, A. Pluzanska, H. P. Kuo, M. Reck, J. Milanowski, J. S.K. Au, E. Felip, P. C. Yang, D. Damyanov, S. Orlov, M. Akimov, P. Delmar, L. Essioux, C. Hillenbach, B. Klughammer, P. McLoughlin, J. Baselga

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed to identify genes with potential use as biomarkers for clinical benefit from erlotinib therapy. Methods: Adults with stage IIIb/IV NSCLC in whom one or more chemotherapy regimen had failed were treated with erlotinib (150 mg/day). Tumour biopsies were analysed using gene expression profiling with Affymetrix GeneChip® microarrays. Differentially expressed genes were verified using quantitative RT-PCR (qRT-PCR). Results: A total of 264 patients were enrolled in the study. Gene expression profiles found no statistically significant differentially expressed genes between patients with and without clinical benefit. In an exploratory analysis in responding versus nonresponding patients, three genes on chromosome 7 were expressed at higher levels in the responding group [epidermal growth factor receptor (EGFR), phosphoserine phosphatase (PSPH) and Rap guanine nucleotide exchange factor 5 (RAPGEF5)]. Independent quantification using qRT-PCR validated the association between EGFR and PSPH overexpression, but not RAPGEF5 overexpression, and clinical outcome. Conclusions: This study supports the use of erlotinib as an alternative to chemotherapy for patients with relapsed advanced NSCLC. Genetic amplification of the EGFR region of chromosome 7 may be associated with response to erlotinib therapy.

Original languageEnglish
Article numbermdp520
Pages (from-to)217-222
Number of pages6
JournalAnnals of Oncology
Volume21
Issue number2
DOIs
Publication statusPublished - Feb 1 2010
Externally publishedYes

Fingerprint

Gene Expression Profiling
Tumor Biomarkers
Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Guanine Nucleotide Exchange Factors
Chromosomes, Human, Pair 7
Patient Selection
Genes
Biomarkers
Drug Therapy
Polymerase Chain Reaction
Transcriptome
Erlotinib Hydrochloride
Biopsy
Therapeutics
Neoplasms
phosphoserine phosphatase

Keywords

  • Biomarkers
  • Epidermal growth factor receptor
  • Erlotinib
  • Gene expression
  • Non-small-cell lung cancer
  • PCR

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. / Tan, E. H.; Ramlau, R.; Pluzanska, A.; Kuo, H. P.; Reck, M.; Milanowski, J.; Au, J. S.K.; Felip, E.; Yang, P. C.; Damyanov, D.; Orlov, S.; Akimov, M.; Delmar, P.; Essioux, L.; Hillenbach, C.; Klughammer, B.; McLoughlin, P.; Baselga, J.

In: Annals of Oncology, Vol. 21, No. 2, mdp520, 01.02.2010, p. 217-222.

Research output: Contribution to journalArticle

Tan, EH, Ramlau, R, Pluzanska, A, Kuo, HP, Reck, M, Milanowski, J, Au, JSK, Felip, E, Yang, PC, Damyanov, D, Orlov, S, Akimov, M, Delmar, P, Essioux, L, Hillenbach, C, Klughammer, B, McLoughlin, P & Baselga, J 2010, 'A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer', Annals of Oncology, vol. 21, no. 2, mdp520, pp. 217-222. https://doi.org/10.1093/annonc/mdp520
Tan, E. H. ; Ramlau, R. ; Pluzanska, A. ; Kuo, H. P. ; Reck, M. ; Milanowski, J. ; Au, J. S.K. ; Felip, E. ; Yang, P. C. ; Damyanov, D. ; Orlov, S. ; Akimov, M. ; Delmar, P. ; Essioux, L. ; Hillenbach, C. ; Klughammer, B. ; McLoughlin, P. ; Baselga, J. / A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. In: Annals of Oncology. 2010 ; Vol. 21, No. 2. pp. 217-222.
@article{abda64656d9b4f219b3f93d379bb70cb,
title = "A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer",
abstract = "Background: Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed to identify genes with potential use as biomarkers for clinical benefit from erlotinib therapy. Methods: Adults with stage IIIb/IV NSCLC in whom one or more chemotherapy regimen had failed were treated with erlotinib (150 mg/day). Tumour biopsies were analysed using gene expression profiling with Affymetrix GeneChip{\circledR} microarrays. Differentially expressed genes were verified using quantitative RT-PCR (qRT-PCR). Results: A total of 264 patients were enrolled in the study. Gene expression profiles found no statistically significant differentially expressed genes between patients with and without clinical benefit. In an exploratory analysis in responding versus nonresponding patients, three genes on chromosome 7 were expressed at higher levels in the responding group [epidermal growth factor receptor (EGFR), phosphoserine phosphatase (PSPH) and Rap guanine nucleotide exchange factor 5 (RAPGEF5)]. Independent quantification using qRT-PCR validated the association between EGFR and PSPH overexpression, but not RAPGEF5 overexpression, and clinical outcome. Conclusions: This study supports the use of erlotinib as an alternative to chemotherapy for patients with relapsed advanced NSCLC. Genetic amplification of the EGFR region of chromosome 7 may be associated with response to erlotinib therapy.",
keywords = "Biomarkers, Epidermal growth factor receptor, Erlotinib, Gene expression, Non-small-cell lung cancer, PCR",
author = "Tan, {E. H.} and R. Ramlau and A. Pluzanska and Kuo, {H. P.} and M. Reck and J. Milanowski and Au, {J. S.K.} and E. Felip and Yang, {P. C.} and D. Damyanov and S. Orlov and M. Akimov and P. Delmar and L. Essioux and C. Hillenbach and B. Klughammer and P. McLoughlin and J. Baselga",
year = "2010",
month = "2",
day = "1",
doi = "10.1093/annonc/mdp520",
language = "English",
volume = "21",
pages = "217--222",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer

AU - Tan, E. H.

AU - Ramlau, R.

AU - Pluzanska, A.

AU - Kuo, H. P.

AU - Reck, M.

AU - Milanowski, J.

AU - Au, J. S.K.

AU - Felip, E.

AU - Yang, P. C.

AU - Damyanov, D.

AU - Orlov, S.

AU - Akimov, M.

AU - Delmar, P.

AU - Essioux, L.

AU - Hillenbach, C.

AU - Klughammer, B.

AU - McLoughlin, P.

AU - Baselga, J.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Background: Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed to identify genes with potential use as biomarkers for clinical benefit from erlotinib therapy. Methods: Adults with stage IIIb/IV NSCLC in whom one or more chemotherapy regimen had failed were treated with erlotinib (150 mg/day). Tumour biopsies were analysed using gene expression profiling with Affymetrix GeneChip® microarrays. Differentially expressed genes were verified using quantitative RT-PCR (qRT-PCR). Results: A total of 264 patients were enrolled in the study. Gene expression profiles found no statistically significant differentially expressed genes between patients with and without clinical benefit. In an exploratory analysis in responding versus nonresponding patients, three genes on chromosome 7 were expressed at higher levels in the responding group [epidermal growth factor receptor (EGFR), phosphoserine phosphatase (PSPH) and Rap guanine nucleotide exchange factor 5 (RAPGEF5)]. Independent quantification using qRT-PCR validated the association between EGFR and PSPH overexpression, but not RAPGEF5 overexpression, and clinical outcome. Conclusions: This study supports the use of erlotinib as an alternative to chemotherapy for patients with relapsed advanced NSCLC. Genetic amplification of the EGFR region of chromosome 7 may be associated with response to erlotinib therapy.

AB - Background: Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed to identify genes with potential use as biomarkers for clinical benefit from erlotinib therapy. Methods: Adults with stage IIIb/IV NSCLC in whom one or more chemotherapy regimen had failed were treated with erlotinib (150 mg/day). Tumour biopsies were analysed using gene expression profiling with Affymetrix GeneChip® microarrays. Differentially expressed genes were verified using quantitative RT-PCR (qRT-PCR). Results: A total of 264 patients were enrolled in the study. Gene expression profiles found no statistically significant differentially expressed genes between patients with and without clinical benefit. In an exploratory analysis in responding versus nonresponding patients, three genes on chromosome 7 were expressed at higher levels in the responding group [epidermal growth factor receptor (EGFR), phosphoserine phosphatase (PSPH) and Rap guanine nucleotide exchange factor 5 (RAPGEF5)]. Independent quantification using qRT-PCR validated the association between EGFR and PSPH overexpression, but not RAPGEF5 overexpression, and clinical outcome. Conclusions: This study supports the use of erlotinib as an alternative to chemotherapy for patients with relapsed advanced NSCLC. Genetic amplification of the EGFR region of chromosome 7 may be associated with response to erlotinib therapy.

KW - Biomarkers

KW - Epidermal growth factor receptor

KW - Erlotinib

KW - Gene expression

KW - Non-small-cell lung cancer

KW - PCR

UR - http://www.scopus.com/inward/record.url?scp=77949502850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949502850&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp520

DO - 10.1093/annonc/mdp520

M3 - Article

C2 - 20110292

AN - SCOPUS:77949502850

VL - 21

SP - 217

EP - 222

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

M1 - mdp520

ER -